10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
CVS HEALTH CORP | |||
Ticker: CVS Fiscal Year: 2019 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 18, 2020) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Cash flows from operating activities: | |||
| Cash receipts from customers | $ 248,393 | 186,519 | 176,594 |
| Cash paid for inventory and prescriptions dispensed by retail network pharmacies | (149,655) | (148,981) | (146,469) |
| Insurance benefits paid | (52,242) | (6,897) | (2,810) |
| Cash paid to other suppliers and employees | (28,932) | (17,234) | (15,348) |
| Interest and investment income received | 955 | 644 | 21 |
| Interest paid | (2,954) | (2,803) | (1,072) |
| Income taxes paid | (2,717) | (2,383) | (2,909) |
| Net cash provided by operating activities | 12,848 | 8,865 | 8,007 |
| Cash flows from investing activities: | |||
| Proceeds from sales and maturities of investments | 7,049 | 817 | 61 |
| Purchases of investments | (7,534) | (692) | (137) |
| Purchases of property and equipment | (2,457) | (2,037) | (1,918) |
| Proceeds from sale-leaseback transactions | 5 | ||
| Proceeds from sale-leaseback transactions | 0 | 265 | |
| Acquisitions (net of cash acquired) | (444) | (42,226) | (1,181) |
| Proceeds from sale of subsidiary and other assets | 0 | 832 | 0 |
| Other | 42 | 21 | 33 |
| Net cash used in investing activities | (3,339) | (43,285) | (2,877) |
| Cash flows from financing activities: | |||
| Net repayments of short-term debt | (720) | (556) | (598) |
| Proceeds from issuance of long-term debt | 3,736 | 44,343 | 0 |
| Repayments of long-term debt | (8,336) | (5,522) | 0 |
| Derivative settlements | (25) | 446 | 0 |
| Repurchase of common stock | 0 | 0 | (4,361) |
| Dividends paid | (2,603) | (2,038) | (2,049) |
| Proceeds from exercise of stock options | 210 | 242 | 329 |
| Payments for taxes related to net share settlement of equity awards | (112) | (97) | (71) |
| Other | 0 | 1 | (1) |
| Net cash provided by (used in) financing activities | (7,850) | 36,819 | (6,751) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 0 | (4) | 1 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 1,659 | 2,395 | (1,620) |
| Cash, cash equivalents and restricted cash at the beginning of the period | 4,295 | 1,900 | |
| Cash, cash equivalents and restricted cash at the end of the period | 5,954 | 4,295 | 1,900 |
| Reconciliation of net income (loss) to net cash provided by operating activities: | |||
| Net income (loss) | 6,631 | (596) | 6,623 |
| Adjustments required to reconcile net income (loss) to net cash provided by operating activities: | |||
| Depreciation and amortization | 4,371 | 2,718 | 2,479 |
| Goodwill impairments | 0 | 6,149 | 181 |
| Loss on settlement of defined benefit pension plans | 0 | 0 | 187 |
| Stock-based compensation | 453 | 280 | 234 |
| Loss on sale of subsidiary | 205 | 86 | 0 |
| Loss on early extinguishment of debt | 79 | 0 | 0 |
| Deferred income taxes | (654) | 87 | (1,334) |
| Other noncash items | 264 | 253 | 53 |
| Change in operating assets and liabilities, net of effects from acquisitions: | |||
| Accounts receivable, net | (2,158) | (1,139) | (941) |
| Inventories | (1,075) | (1,153) | (514) |
| Other assets | (614) | (3) | (338) |
| Accounts payable and pharmacy claims and discounts payable | 3,550 | 2,329 | 1,710 |
| Health care costs payable and other insurance liabilities | 320 | (311) | 0 |
| Other liabilities | 1,476 | 165 | (333) |
| External Links | |
| CVS HEALTH CORP (CVS) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |